Atria Investments Inc Has $832,000 Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Atria Investments Inc increased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 57.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 56,613 shares of the company’s stock after purchasing an additional 20,760 shares during the period. Atria Investments Inc’s holdings in Elanco Animal Health were worth $832,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Davidson Kempner Capital Management LP acquired a new stake in shares of Elanco Animal Health during the 2nd quarter worth approximately $839,000. Price T Rowe Associates Inc. MD increased its stake in Elanco Animal Health by 4.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock valued at $360,425,000 after purchasing an additional 852,281 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Elanco Animal Health during the second quarter valued at about $55,599,000. XTX Topco Ltd acquired a new position in shares of Elanco Animal Health during the second quarter valued at about $935,000. Finally, SG Capital Management LLC bought a new position in shares of Elanco Animal Health during the 1st quarter worth about $4,211,000. 97.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was bought at an average cost of $14.85 per share, with a total value of $51,975.00. Following the completion of the transaction, the director now owns 81,094 shares of the company’s stock, valued at $1,204,245.90. The trade was a 4.51 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.57% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Barclays upped their price target on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a research report on Thursday, September 19th. Finally, Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.14.

Elanco Animal Health Stock Down 3.8 %

ELAN stock opened at $13.45 on Tuesday. The firm has a market capitalization of $6.65 billion, a PE ratio of 33.63, a P/E/G ratio of 1.46 and a beta of 1.41. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a twelve month low of $11.40 and a twelve month high of $18.80. The stock’s 50 day moving average is $13.79 and its 200-day moving average is $14.77.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the business earned $0.18 EPS. The business’s revenue was down 3.6% on a year-over-year basis. Sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.